Session Details

PRL07 Phenotyping Hidradenitis Suppurativa (HS): Findings of a Collaborative Artificial Intelligence (AI) Initiative

Sat, Jul 18, 1:00 PM - 12:00 AM
Trianon Ballroom
0.75 CME Available Pearls
View Map

DESCRIPTION

This session will present how innovative AI modeling identified a distinct hidradenitis suppurativa (HS) phenotype comprising data elements from patients' health histories. This phenotype distinguished HS patients who may otherwise remain undiagnosed from the broader population, providing clinical insight and the potential for reduced time to diagnosis and treatment. In this session, attendees will learn about the HS phenotype discovered through an unique AAD-based project and gain insights into examples of cases which align with our study findings

LEARNING OBJECTIVES

1.

Demonstrate how a heterogeneous open claims data source augmented with EHR data identified patients with hidradenitis suppurativa (HS).

2.

Examine how AI isolated disease profiles to identify at-risk patients in real-world datasets

3.

Diagnose more challenging HS cases which align with the findings of the study.

SCHEDULE

1:00 PM

Our AI model for finding undiagnosed HS: Overview

Steven Daniel Daveluy, MD, FAAD

1:10 PM

Discussion

Martina J. Porter, MD, FAAD

1:20 PM

Discussion

Amit Garg, MD, FAAD

1:30 PM

Questions and Answers

DIRECTOR

Steven Daniel Daveluy, MD, FAAD

Steven Daniel Daveluy, MD, FAAD

Wayne State University

SPEAKER

Amit Garg, MD, FAAD

Amit Garg, MD, FAAD

Northwell Health

HANDOUTS

Login to view handouts

DISCLOSURES

Steven Daniel Daveluy, MD, FAAD

AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);

Amit Garg, MD, FAAD

AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Bluefin Biomedicine – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Leo Pharma – Advisory Board(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);